Drugs / XY0206
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT07162116 | Jul → Dec 2025 overdue | acute myeloid leukemia, FLT3 internal tandem duplication | Shijiazhuang Yiling Pharmaceutical Co. Ltd | Recruiting | No outcome recorded |
| Phase 1 | NCT06823232 | Nov → Dec 2024 | — | Shijiazhuang Yiling Pharmaceutical Co. Ltd | Completed | No outcome recorded |
| Phase 1 | NCT04471064 | Sep 2020 → Feb 2024 | acute myeloid leukemia | Shijiazhuang Yiling Pharmaceutical Co. Ltd | Unknown | No outcome recorded |
| Phase 1 | NCT03658070 | Dec 2018 → Dec 2020 | — | Shijiazhuang Yiling Pharmaceutical Co. Ltd | Unknown | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT05876832 | Jun 2023 → Jul 2027 expected | acute myeloid leukemia, FLT3 internal tandem duplication | Shijiazhuang Yiling Pharmaceutical Co. Ltd | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | XY0206 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07162116 ↗ |
| Action | Inhibit | “This Phase I/II clinical trial (NCT04471064) evaluated the preliminary efficacy, safety, and pharmacokinetics of XY0206, a novel oral FMS-like tyrosine kinase 3 (FLT3)...” PMID 42015516 ↗ Apr 2026 |
| Route | Oral | “oral XY0206” NCT03658070 ↗ |
| Target | FLT3 | “This Phase I/II clinical trial (NCT04471064) evaluated the preliminary efficacy, safety, and pharmacokinetics of XY0206, a novel oral FMS-like tyrosine kinase 3 (FLT3)...” PMID 42015516 ↗ Apr 2026 |